key: cord-0842836-9rfx5v1a
authors: Butler-Laporte, G.; Povysil, G.; Kosmicki, J.; Cirulli, E. T.; Drivas, T.; Furini, S.; Saad, C.; Schmidt, A.; Olszewski, P.; Quinodoz, M.; Celik, E.; Kundu, K.; Walter, K.; Jung, J.; Stockwell, A. D.; Sloofman, L. G.; Charney, A. W.; Jordan, D.; Beckmann, N.; Przychodzen, B.; Chang, T.; Pottinger, T. D.; Shang, N.; Brand, F.; Fava, F.; Mari, F.; Chwialkowska, K.; Niemira, M.; Korotko, U.; Pula, S.; Baillie, J. K.; Stuckey, A.; Ganna, A.; Karczewski, K. J.; Veerapen, K.; Bourgey, M.; Bourque, G.; Eveleigh, R. J.; Forgetta, V.; Morrison, D.; Langlais, D.; Lathrop, M.; Mooser, V.; Nakanishi, T.
title: Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
date: 2022-03-30
journal: nan
DOI: 10.1101/2022.03.28.22273040
sha: b3c43fcc8d1393c6cc04ad58d81216452f191223
doc_id: 842836
cord_uid: 9rfx5v1a

Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,048 severe disease cases and 571,009 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41x10-7). These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID- 19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined wholeexome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,048 severe disease cases and 571,009 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41x10 -7 ). These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Despite successful vaccine programs, SARS-CoV-2 is still a major cause of mortality and widespread societal disruption 1, 2 . While disease severity has correlated with well established epidemiological and clinical risk factors (e.g., advanced age, obesity, immunosuppression), these do not explain the wide range of COVID-19 presentations 3 . Hence, individuals without one of these known risk factors may have a genetic predisposition to severe COVID-19 4 . These genetic determinants to severe disease can, in turn, inform about the pathophysiology underlying COVID-19 severity and accelerate therapeutics development 5, 6 .

Previous work on COVID-19 host genetics using genome-wide association studies (GWASs) revealed 23 statistically robust genetic loci associated with either COVID-19 severity or susceptibility [7] [8] [9] [10] [11] . Given that most GWASs use genetic data obtained from genome-wide genotyping followed by imputation to measure the association between a phenotype and genetic variation, their reliability and statistical power declines as a variant's frequency decreases, especially at allele frequencies of less than 1% 12 . Ascertainment of rare genetic variation can be improved with sequencing technology 13 . Rare variants are expected to be enriched for larger effect sizes, due to evolutionary pressure on highly deleterious variants, and may therefore provide unique insights into genetic predisposition to COVID-19 severity. Identifying such genes may highlight critical control points in the host response to SARS-CoV-2 infection.

Measuring the effect of rare genetic variants on a given phenotype (here COVID-19) is difficult. Specifically, while variants of large effect on COVID-19 are more likely to be rare, the converse is not true, and most rare variants are not expected to strongly impact COVID-19 severity 14 . Therefore, unless large sample sizes and careful statistical adjustments are used, most rare variant genetic associations studies risk being underpowered, and are at higher risk of false or inflated effect estimates if significant associations are found between COVID-19 and genetic loci. This is exemplified by the fact that several rare variant associations reported for COVID-19 have not been replicated in independent cohorts [15] [16] [17] .

Here, we investigated the association of rare genetic variants on the risk of COVID-19 by combining gene burden test results from whole exome and whole genome sequencing. To our knowledge, this is the first rare genetic variant burden test meta-analysis ever performed on a worldwide scale, including 21 cohorts, in 12 countries, including all main continental genetic ancestries.

The final analysis included up to 28,159 individuals infected with SARS-CoV-2, and up to 596,189 controls from 21 cohorts in 12 countries (Figure 1) . Most participants were of European genetic ancestry (n=576,389), but the consortium also included participants of Admixed American (n=4,529), African (n=25,465), East Asian (n=4,058), Middle Eastern (n=4,977) and South Asian ancestries (n=9,943). Participating cohorts enrolled patients based on local protocols, and both retrospective and prospective designs were used. Genetic sequencing was also performed locally, and cohorts were provided with a specific framework for quality control analyses, but each were allowed to deviate based on individual needs. Both exome (n = 11 cohorts) and genome sequencing (n = 10 cohorts) were included in the meta-analyses. The mean age of participants was 55.7, and 55.9% were females.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 30, 2022. ;  We studied three separate outcome phenotypes, as previously described by the COVID-19 Host Genetics Initiative (COVID-19 HGI) 8 . Briefly, the outcome cases were defined according to three standard COVID-19 HGI outcomes: A) severe disease: individuals with SARS-CoV-2 infection who died or required invasive respiratory support (extracorporeal membrane oxygenation, intubation with mechanical ventilation, high-flow oxygen support, or new bilevel or continuous positive airway pressure ventilation), B) hospitalisation: individuals with SARS-CoV-2 who died or required hospitalisation, and C) susceptibility to infection: any individual with SARS-CoV-2 infection. These are also referred to as A2, B2, and C2, respectively, in the COVID-19 HGI meta-analyses 8 . For all three phenotypes, controls were all individuals not classified as cases (including population controls with unknown COVID-19 status). The final meta-analyses included up to 5,048 cases and 571,009 controls for the severe disease outcome, 12,267 cases and 589,175 controls for the hospitalisation outcome, and 28,159 cases and 596,189 controls for the susceptibility outcome.

Given the expected paucity of large-effect size rare deleterious variants, strategies have been devised to increase statistical power to test associations between rare variants and biomedically-relevant outcomes. One such strategy is to use burden tests 18 , where each variant is collapsed into larger sets of variants, and association is tested between groups of variants and an outcome. Here, we collapsed deleterious variants in each gene and devised the following burden test: for each gene, an individual received a score of 0 if they do not carry any deleterious variant, a score of 1 if they carry at least one nonhomozygous deleterious variant, and a score of 2 if they carry at least 1 homozygous deleterious variant. Similar to previous studies on burden testing of rare variants 17, 19 deleterious variants were chosen using three masks: 1) "pLoF" which uses only predicted loss of function variants, 2) "coding5" which uses all variants in pLoF, as well as indels of moderate consequence as predicted by Ensembl 20 , and missense variants classified as deleterious in 5 in-silico algorithms (see Methods), and 3) "coding1", which uses all variants in coding5 and coding5, and also adds all missense variants classified as deleterious in at least 1 of the in-silico algorithms. The analyses were performed for variants with minor allele frequency (MAF) between < 1% and < 0.1%. MAFs were obtained from a combination of gnomAD 21 and cohort-specific common variant exclusion lists. These common variant lists included variants that achieved a MAF of >1 % or > 0.1 % in at least one study population within the consortium. To reduce the effect of fluctuations due to sampling, a minor allele count (MAC) ≥ 6 in the corresponding study was required for inclusion in the common variant list. Such "blacklists" have been shown to increase statistical power by removing variants at lower risk of being highly deleterious, and it reduces the risk of having cohort-specific false-positive variants being retained on the overall analysis 22 .

The resulting score (either 0, 1, or 2) for each mask was then regressed on each of our three phenotypes using logistic regression, controlling for age, age^2, sex, sex*age, sex*age^2, and 10 common variant (MAF > 1%) genetic principal components (the same covariates as for COVID-19 HGI GWASs 7,8 ). Additionally, given that population genetic structure and its confounding effect on phenotypes is different at the rare variant level 23 , we also used the first 20 genetic principal components from rare variants (MAF<1%) as covariates in all our analyses. Analyses were performed separately by each cohort and each ancestry using Firth regression as applied in the Regenie software 24 . Firth regression is a penalized likelihood regression method that provides unbiased effect . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  estimates even in highly unbalanced case-control analyses, as expected with rare variants 25 . The summary statistics were then meta-analyzed with a fixed effect inversevariance weighted model within each ancestry, and then with a DerSimonian-Laird random effect model across ancestries.

Our meta-analysis included a total of 18,883 protein-coding genes, and all burden test genetic inflation factors, for all masks, were less than 1, suggesting that our results were not biased by population stratification and that Firth regression adequately adjusted for unbalanced case-control counts. Using an exome-wide significance p-value threshold of 0.05/20,000 = 2.5x10 -6 , we found 3 genes associated with one of the COVID-19 phenotypes in at least one mask in our meta-analyses ( Table 1) . Of specific interest, we observed that carrying a predicted loss of function (pLoF) or missense variant (mask coding5) in the toll-like receptor 7 (TLR7) gene was associated with a 5.3-fold increase (95% CI: 2.7-10.1, p=5.41x10 -7 ) in odds of severe COVID-19. TLR7 is an important part of the innate viral immunity, encoding a protein that recognizes coronaviruses and other single-stranded RNA viruses, leading to upregulation of the type-1 and type-2 interferon pathway 26 . Results from the severe COVID-19 outcome analyses of TLR7 with other masks also nearly reach our statistical significance threshold, with larger effects found in the pLoF mask (OR: 13.6, 95% CI: 4.41-44.3, p=1.64x10 -5 ) and smaller effect in the coding1 mask (OR: 3.12, 95% CI: 1.91-5.10, p=5.30x10 -6 ), though the latter was balanced by smaller standard errors due to the larger number of cases (3275 cases in coding1 vs 1577 in pLoF), as expected. These findings further support previous reports of TLR7 errors of immunity underlying severe COVID-19 presentations 17,27-30 .

In the meta-analyses, we also found that pLoFs in MARK1 were associated with a 23.9fold increase in the odds of severe COVID-19 (95% CI: 6.5-88.2, p=1.89x10 -6 ), and a 12.3-fold increase in the odds of hospitalisation due to COVID-19 (95% CI: 4.8-31.2, p=1.43x10 -7 ). While the number of MARK1 pLoFs found in severe and hospitalized cases was small (MAC=4 and MAC=8, respectively), the signal was consistent in our three largest cohorts: UK Biobank, Penn Medicine, and Geisinger Health Services. MARK1 is a member of the microtubule affinity-regulating kinase family, and is involved in multiple biological processes, chief among which is the promotion of microtubule dynamics 31 . MARK1 has previously been shown to interact with the SARS-CoV-2 ORF9b protein 32 , further supporting its potential role in COVID-19. Lastly, our metaanalyses also found marginal evidence for an association between severe COVID-19 and pLoFs in RILPL1 (OR: 20.2, 95% CI: 5.8-70.7, p=2.42x10 -6 ), a gene that, like MARK1, is associated with microtubule formation and ciliopathy 33 .

When we meta-analyzed p-values using the aggregated Cauchy association test 34 (ACAT), the association between TLR7 and severe COVID-19 (p=1.58x10 -6 ), and between MARK1 and hospitalisation (p=4.30x10 -7 ) remained exome-significant ( Figure  2) . Full summary statistics are available in Supp. Table 6 .

Rare variants in interferon-related genes and at previously reported genome-wide significant loci Despite a 7.7-fold increase in number of cases, and a 1,069-fold increase in number of controls, the previously reported associations of genes in the interferon pathway with COVID-19 outcomes 15, 16 could not be replicated with either our exome-wide significance threshold (Supp. Table 7 ) or a more liberal one of p=0.05/10=0.005 (based on . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  Bonferroni correction by the number of genes in the interferon pathway defined in a previous study 15 ).

We also tested for rare variant associations between GWAS candidate genes from genome-wide significant loci in the COVID-19 HGI GWAS meta-analyses, but observed no exome-wide significant associations (Supp Table 8 ). However, at a more liberal Bonferroni threshold of p=0.05/46=0.001 (correcting for the 46 genes in the COVID-19 HGI GWAS associated loci), we observed an increased burden of pLOF or missense variants (coding5 mask) in ABO gene among those susceptible to SARS-CoV-2 infection. For example, individuals carrying a pLoF with MAF<0.1% in ABO were at a 2.34-fold higher risk of having a positive SARS-CoV-2 infection (95% CI: 1.50-3.64, p=1.6x10 -4 ). Note that deleterious variants in ABO often lead to blood groups A and B 35, 36 , which is consistent with the epidemiological association that non-type-O individuals are at higher risk of COVID-19 37 . However, more work is required to better understand the genetics of this locus as it relates to COVID-19 outcomes. Lastly, missense variants in NSF (mask coding1, MAF<1%) were also associated with higher susceptibility to SARS-CoV-2 (OR: 1.48, 95% CI: 1.21-1.82, p=1.4x10 -4 ), but this association was not present in other masks (Supp Table 8 ).

Data for the pLoF mask for TLR7 and MARK1 in the severe COVID-19 phenotype was then replicated with the GenOMICC cohort 11 , a prospective study enrolling critically ill individuals with COVID-19, with controls selected from the 100,000 genomes cohort 38 . Results are shown in Table 2 . For TLR7, European ancestry individuals with a pLoF had a 4.70-fold increase in odds of severe disease (95% CI: 1.58 to 14.0, p=0.005). In the sample of South Asian ancestry individuals, a pLoF was associated with a 1.90-fold increase in odds of severe disease, but the 95% confidence interval crossed the null (0.23 to 15.6, p=0.55), which was likely due to a much smaller sample size than in the European ancestry subgroup (1,202 vs 10,645). Of interest, in both Europeans and South Asians, no pLoFs were observed in either of the control groups.

On the other hand, we could not replicate an effect from MARK1, which demonstrated an OR of 1.21 in European ancestry participants (95% CI 0.075 to 19.7, p=0.89) and an OR of 4.21 in South Asian ancestry individuals (95% CI 0.058 to 307, p=0.51).

We performed an exome-wide association study using single variants with MAF higher than 0.1% and allele count of 6 or more, with the same analysis design used in the COVID-19 HGI GWAS 8 , and the same outcome phenotypes used in the burden testing above. The previously described Neanderthal chromosome 3 locus associated with COVID-19 outcomes was also found in all three phenotypes, with lead variants in the FYCO1 gene for the severe COVID-19 and hospitalisation phenotypes (rs13059238 and rs41289622, respectively), and for the LIMD1 gene in the susceptibility phenotype (rs141045534). One other variant was found in the hospitalisation phenotype in SRRM1 (rs1479489847); this association was found in only two of our smaller cohorts (Genentech EUR and AMR ancestries, and Vanda EUR ancestry), and was not replicated in the larger ones (p=0.30 in the UK Biobank EUR ancestry). Summary statistics for genome-wide significant variants can be found in Supp. Table 9 , and Manhattan plots can be found in the Supp. Figures.

.

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  Whole genome and whole exome sequencing can provide unique insights into genetic determinants of COVID-19, by uncovering associations between rare genetic variants and COVID-19. Specifically, burden tests can be particularly helpful, because they test for coding variants, thereby pointing directly to a causal gene and often suggesting a direction of effect. However, such studies require careful control for population stratification and an adapted analysis method such as burden testing, in order to have enough statistical power to find those associations. In our study, we observed that individuals with rare deleterious variants at TLR7 are at increased risk of severe COVID-19 (up to 13.1-fold increase in odds in those with pLoFs). Although this association was suggested by previous studies 27- 29 , our study provides the most definitive evidence for the role of TLR7 in COVID-19 pathogenesis, with exome-wide significance for this gene in the discovery phase followed by strong replication in a large independent cohort. TLR7 is a well-studied part of the antiviral immunity cascade and stimulates the interferon pathway after recognizing viral pathogen-associated molecular patterns.

We also uncovered a potential role for cellular microtubule disruption in the pathogenesis of COVID-19 and the microtubule network is known to be exploited by other viruses during infections 39 . Indeed, the MARK1 protein has been shown to interact with SARS-CoV-2 in previous in-vitro experiments 32 . Nevertheless, these findings at MARK1 were not replicated in the GenOMICC cohort and will need to be tested in larger cohorts, especially given the small number of highly deleterious variants that we found in our consortium.

To our knowledge, this is the first time a rare variant burden test meta-analysis has been attempted on such a large scale. Our framework allowed for easy and interpretable summary statistics results, while at the same time preventing participant de-identification or any breach of confidentiality that stems from sharing results of rare genetic variant analyses 40 . It also provides important insights into how these endeavours should be planned in the future. First, our burden test operated under the assumption that the effect of any of the deleterious variants on the phenotype would be in the same direction and did not account for compound deleterious variant heterozygosity. This allowed for easier meta-analysis across cohorts but may have decreased statistical power. Other methods may be needed in future analysis to soften this assumption, though some of these cannot be easily meta-analyzed across multiple cohorts directly from summary statistics (e.g., SKAT-O 41 ). Similarly, methods that combine both rare and common variants might also provide additional insights into disease outcomes 30, 42 . Second, our results highlight the importance at looking at different categories of variants through different masks to increase sensitivity and specificity of our burden tests. Lastly, work remains to be done to standardize sequencing and annotation pipelines to allow comparisons of results easily across studies and cohorts. Here, we provided a pipeline framework to evert participating cohorts, but there remains room for process harmonization in the future.

Our study had limitations. First, even if this is one of the world's largest consortia using sequencing technologies for the study of rare variants, we remain limited by a relatively small sample size. For example, in a recent analyses of UK Biobank exomes, many of the phenotypes for which multiple genes were found using burden tests had a much higher number of cases than in our analyses (e.g. blonde hair colour, with 48,595 cases) 19 . Further, rare variant signals were commonly found in regions enriched in common variants found in GWASs. The fact that ABO and NSF were the only genes from the COVID-19 HGI GWAS that were also identified in our burden test (albeit using . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  a more liberal significance threshold), also suggests a lack of statistical power. Similarly, GenOMICC, a cohort of similar size, was also unable to find rare variant associations using burden tests 11 . However, their analysis methods were different from ours, making further comparisons difficult. Nevertheless, this provides clear guidance that smaller studies looking at the effect of rare variants across the genome are at considerable risk of finding both false positive and false negative associations. Second, many cohorts used population controls, which may have decreased statistical power given that some controls may have been misclassified. However, given that COVID-19 critical illness remains a rare phenomenon 43 , our severe disease phenotype results are unlikely to be strongly affected by this. Further, the use of population control is a long-established strategy in GWAS burden tests 7, 8, 11, 19, 44 , and the statistical power gain from increasing our sample size is likely to have counter-balanced the misclassification bias.

In summary, we reproduced an exome-wide significant association with severe COVID-19 outcomes in carriers of rare deleterious variants at TLR7. Our results also suggest an association between the cellular microtubule network and severe disease, which requires further validation. More importantly, our results underline the fact that future genome-wide studies of rare variants will require considerably larger sample size, but our work provides a roadmap for such collaborative efforts.

For all analyses, we used three case-control definitions: A) Severe COVID-19, where cases were those who died, or required either mechanical ventilation (including extracorporeal membrane oxygenation), high-flow oxygen supplementation, new continuous positive airway pressure ventilation, or new bilevel positive airway pressure ventilation, B) Hospitalized COVID-19, where cases were all those who died or were admitted with COVID-19, and C) Susceptibility to COVID-19, where cases are anyone who tested positive for COVID-19, self-reported an infection to SARS-CoV-2, or had a mention of COVID-19 in their medical record. For all three, controls were individuals who did not match case definitions, including population controls for which case status was unknown (given that most patients are neither admitted with COVID-19, nor develop severe disease 45 ). These three analyses are also referred to as analyses A2, B2, and C2 by the COVID-19 Host Genetics Initiative 8 , respectively.

Any cohort with access to genetic sequencing data and the associated patient level phenotypes were allowed in this study. Specifically, both whole-genome and wholeexome sequencing was allowed, and there were no limitations in the platform used. There were no minimal number of cases or controls necessary for inclusion. However, the first step of Regenie, which was used to perform all tests (see below), uses a polygenic risk score which implicitly requires that a certain sample size threshold be reached (which depends on the phenotype and the observed genetic variation). Hence, cohorts were included if they were able to perform this step. All cohorts obtained approval from their respective institutional review boards, and informed consent was obtained from all participants. More details on each cohort's study design and ethics approval can be found in the Supp Tables 1-2.

Variant calling and quality control Variant calling was performed locally by each cohort, with the pre-requisite that variants not be joint-called separately between cases and controls. Quality control was also . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  performed individually by each cohort according to individual needs. However, a general quality control framework was made available using the Hail software 46 . This included variant normalization and left alignment to a reference genome, removal of samples with call rate less than 97% or mean depth less than 20. Genotypes were set to unknown if they had genotype quality less than 20, depth less than 10, or poor allele balance (more than 0.1 for homozygous reference calls, less than 0.9 for homozygous alternative calls, and either below 0.25 or above 0.75 for heterozygous calls. Finally, variants were removed from if the mean genotype quality was less than 11, mean depth was less than 6, mean call rate less than or equal to 0.8, and Hardy-Weinberg equilibrium p-value less than or equal to 5x10 -8 (10 -16 for single variant association tests). Details on variant calling and quality control is described for each cohort in the Supp. Table 1 .

For the burden tests, we also compiled a list of variants that had a MAF > 1 % or > 0.1 % in any of the participating cohorts. This list was used to filter out variants that were less likely to have a true deleterious effect on COVID-19, even if they were considered rare in other cohorts, or in reference panels 22 . We created two such variant exclusion lists: one to be used in our burden test with variants of MAF less than 1%, and the other for the analysis with MAF less than 0.1%. In any cohort, if a variant had a minor allele count of 6 or more, and a MAF of more than 1% (or 0.1%), this variant was added to our exclusion list. This list was then shared with all participating cohorts, and all variants contained were removed from our burden tests.

The following analyses generally followed the methods used by recent literature on large-scale whole-exome sequencing 19 and the COVID-19 HGI 8 .

The burden tests were performed by pooling variants in three different variant sets (called masks): "pLoF" which included loss of functions as defined by high impact variants in the Ensembl database 20 (i.e. transcript ablation, splice acceptor variant, splice donor variant, stop gained, frameshift variant, stop lost, start lost, transcript amplification), "coding5" which included all variants in pLoF as well as moderate impact indels and any missense variants that was predicted to be deleterious based on all of the in-silico pathogenicity prediction scores used, and "coding1" which included all variants in coding5 as well as all missense variants that were predicted to be deleterious in at least one of the in-silico pathogenicity prediction scores used. For in-silico prediction, we used the following five tools: SIFT 47 , LRT 48 , MutationTaster 49 , PolyPhen2 50 with the HDIV database, and PolyPhen2 with the HVAR database. Protein coding variants were collapsed on canonical gene transcripts. Masks pLoF, coding5, and coding1 are equivalent to masks M1, M3, and M4, respectively, from the recent UK Biobank wholeexome sequencing paper by Backman et al. 19 and Kosmicki et al. 17 .

Once variants were collapsed into genes in each participant, for each mask, genes were given a score of 0 if the participant had no variants in the mask, a score of 1 if the participant had one or more heterozygous variant in this mask, and a score of 2 if the participant had one or more homozygous variant in this mask. These scores were used as regressors in logistic regression models for the three COVID-19 outcomes above. These regressions were also adjusted for age, age*age, sex, age*sex, age*age*sex, 10 genetic principal components obtained from common genetic variants (MAF>1%), and 20 genetic principal components obtained from rare genetic variants (MAF<1%). The Regenie software 24 was used to perform all burden tests, and generate the scores . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ;  above. Regenie uses Firth penalized likelihood to adjust for rare or unbalanced events, providing unbiased effect estimates.

All analyses were performed separately for each of 6 genetic ancestries (African, Admixed American, East Asian, European, Middle Eastern, and South Asian). Summary statistics were then meta-analyzed using a fixed effect model within each ancestry and using a DerSimonian-Laird random effect model across ancestries with the Metal package 51 and its random effect extension 52 . Participant assignment to genetic ancestry was done locally by each cohort, more details on the methods can be found in the Supp. Table 1 .

Lastly, we used ACAT 34 to meta-analyze p-values across masks, within each phenotype separately. ACAT is not affected by lack of independence between tests. These values were used to draw Manhattan and QQ plots in Figure 2 .

We performed single variant association tests using a GWAS additive model framework. We used the same COVID-19 outcomes and covariates as above, except for the addition of the 20 rare genetic variant principal components. Once again, each cohort performed their analyses separately for each genetic ancestry, but also restricted their variants to those with MAF>0.01% and MAC>6. Summary statistics were meta-analyzed as above. Lastly, given that multiple technologies were used for sequencing, and that whole-exome sequencing can provide variant calls of worse quality in its off-target regions 53 , we used the UKB, GHS, and Penn Medicine whole-exome sequencing variants as our "reference panel" for whole-exome sequencing. Hence, only variants reported in at least one of these biobanks were used in the final analyses.

Code guidance is available at https://github.com/DrGBL/WES.WGS.

The exome-wide burden test summary statistics are available in the Supplements. The single variant association studies summary statistics will be made available openly on the GWAS Catalog 54 . Figure 1 : Maps of countries contributing data to the consortium. Sample sizes (cases and controls) for each phenotype were added and represented on the logarithmic scale by each circle. Relative contribution to each phenotype is represented by the three colors.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 30, 2022. ; https://doi.org/10.1101/2022.03.28.22273040 doi: medRxiv preprint Figure 2 : Exome burden test ACAT p-value meta-analysis Manhattan plots and QQ plots.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint 

Impact of the COVID-19 pandemic on a tertiary care public hospital in Singapore: Resources and economic costs

Impact of COVID-19 on accident and emergency attendances and emergency and planned hospital admissions in Scotland: an interrupted time-series analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity

Actionable druggable genomewide Mendelian randomization identifies repurposing opportunities for COVID-19

Mapping the human genetic architecture of COVID-19: an update

Mapping the human genetic architecture of COVID-19

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Genetic mechanisms of critical illness in COVID-19

Whole genome sequencing reveals host factors underlying critical Covid-19

Benefits and limitations of genome-wide association studies

Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program

Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19

Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals

The Increasing Importance of Gene-Based Analyses

Exome sequencing and analysis of 454,787 UK Biobank participants

The mutational constraint spectrum quantified from variation in 141,456 humans

Blacklisting variants common in private cohorts but not in public databases optimizes human exome analysis

Differential confounding of rare and common variants in spatially structured populations

Computationally efficient whole-genome regression for quantitative and binary traits

Firth logistic regression for rare variant association tests

27 van der Made CI, Simons A, Schuurs-Hoeijmakers J, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19

Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested casecontrol study

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients

MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

The Rilp-like proteins Rilpl1 and Rilpl2 regulate ciliary membrane content

ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies

Molecular Basis of ABO Variants Including Identification of 16 Novel ABO Subgroup Alleles in Chinese Han Population

Weak A phenotypes associated with novel ABO alleles carrying the A2-related 1061C deletion and various missense substitutions

000 Genomes Pilot on Rare-Disease Diagnosis in Health Care -Preliminary Report

Microtubules in Influenza Virus Entry and Egress

Genomic privacy and limits of individual detection in a pool

Optimal Unified Approach for Rare-Variant Association Testing with Application to Small-Sample Case-Control Whole-Exome Sequencing Studies

Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data

Factors associated with COVID-19-related death using OpenSAFELY

Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts

Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants

SIFT missense predictions for genomes

Identification of deleterious mutations within three human genomes

MutationTaster evaluates disease-causing potential of sequence alterations

Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2

METAL: fast and efficient meta-analysis of genomewide association scans

random-metal. GitHub Repos

Exome sequencing generates high quality data in nontarget regions

The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019

We thank the patients who volunteered to all participating cohorts, and the researchers and clinicians who enrolled them into the respective studies. A full list of acknowledgements can be found in Supp. Table 2 . 

See Supp. Table 2 .

J Brent Richards is the corresponding author (brent.richards@mcgill.ca).